Background Hibernoma is a rare benign tumor of adults that is composed of multivacuolated adipocytes resembling brown fat cells. Hibernoma typically occurs in soft tissue, and intraosseous examples are very rare. Intraosseous hibernomas can radiologically mimic metastatic carcinoma and other tumorous conditions. Methods: To collect the intraosseous hibernomas, we searched the pathologic database and reviewed the hematoxylin and eosin (H&E)–stained slides of bone biopsy samples performed to differentiate radiologically abnormal bone lesions from 2006 to 2016. A total of six intraosseous hibernoma cases were collected, and clinical and radiological information was verified from electronic medical records. H&E slide review and immunohistochemical staining for CD68, pan-cytokeratin, and S-100 protein were performed. Results: Magnetic resonance imaging of intraosseous hibernomas showed low signal intensity with slightly hyperintense foci on T1 and intermediate to high signal intensity on T2 weighted images. Intraosseous hibernomas appeared as heterogeneous sclerotic lesions with trabecular thickening on computed tomography scans and revealed mild hypermetabolism on positron emission tomography scans. Histopathologically, the bone marrow space was replaced by sheets of multivacuolated, foamy adipocytes resembling brown fat cells, without destruction of bone trabeculae. In immunohistochemical analysis, the tumor cells were negative for CD68 and pan-cytokeratin and positive for S-100 protein. Conclusions: Intraosseous hibernoma is very rare. This tumor can be overlooked due to its rarity and resemblance to bone marrow fat. Pathologists need to be aware of this entity to avoid misdiagnosis of this rare lesion.
Citations
Citations to this article as recorded by
A Rare Case of Large Lateral Chest Wall Hibernoma Lyubomir Gaydarski, Boycho Landzhov, Ivaylo Kamenov, Julian M Ananiev, Georgi P Georgiev Cureus.2024;[Epub] CrossRef
Intraosseous hibernoma mimicking sclerotic bone metastasis—a case report Ali Shaikh, Adil Basha, George Ray, Justin A. Bishop, Avneesh Chhabra Skeletal Radiology.2024;[Epub] CrossRef
Femoral hibernoma: unique intraosseous tumor Gökhan Tonkaz, Ertugrul Cakir, Mehmet Tonkaz, Demet Sengul Wiener klinische Wochenschrift.2024; 136(19-20): 581. CrossRef
Unusual Imaging Findings of Epithelioid Hemangioma: Case Report of Single Intramedullary Sclerotic Bone Lesion Yun Chul Hwang, Tae Eun Kim, Jae Hyuck Yi Journal of the Korean Society of Radiology.2024; 85(5): 986. CrossRef
Benign incidental do-not-touch bone lesions Nuttaya Pattamapaspong, Wilfred CG Peh The British Journal of Radiology.2023;[Epub] CrossRef
Intraosseous hibernoma: clinicopathologic and imaging analysis of 18 cases Chiraag N Gangahar, Carina A Dehner, David P Wang, Behrang Amini, Travis Hillen, Christopher O'Conor, Sydney N Jennings, Kathleen Byrnes, Elizabeth A Montgomery, Bogdan A Czerniak, Julia A Bridge, Molly C Schroeder, Jack W Jennings, Wei‐Lien Wang, John S Histopathology.2023; 83(1): 40. CrossRef
Intraosseous Hibernoma: A Rare Entity in Orthopedics With Peculiar Radiological Features Ramy Samargandi, Louis-Romée Le Nail, Gonzague de Pinieux, Matthias Tallegas, Elodie Miquelestorena-Standley Cureus.2023;[Epub] CrossRef
Intraosseous hibernoma of the appendicular skeleton Salvatore Gitto, Thom Doeleman, Michiel A. J. van de Sande, Kirsten van Langevelde Skeletal Radiology.2022; 51(6): 1325. CrossRef
Intraosseous hibernoma: Two case reports and a review of the literature Samantha N. Weiss, Ankit Mohla, Gord Guo Zhu, Christina Gutowski, Tae Won B Kim, Rohan Amin Radiology Case Reports.2022; 17(7): 2477. CrossRef
Hibernoma of two contiguous vertebrae: uniqueness of a lesion already rare in itself Donato MASTRANTUONO, Domenico MARTORANO, Guido REGIS, Federica ARABIA, Alessandra LINARI, Federica SANTORO Journal of Radiological Review.2022;[Epub] CrossRef
Primary extradural tumors of the spinal column Varun Arvind, Edin Nevzati, Maged Ghaly, Mansoor Nasim, Mazda Farshad, Roman Guggenberger, Daniel Sciubba, Alexander Spiessberger Journal of Craniovertebral Junction and Spine.2021; 12(4): 336. CrossRef
Spinal Intraosseous Hibernoma: A Case Report and Review of Literature Mi-Kyung Um, Eugene Lee, Joon Woo Lee, Kyu Sang Lee, Yusuhn Kang, Joong Mo Ahn, Heung Sik Kang Journal of the Korean Society of Radiology.2020; 81(4): 965. CrossRef
Intraosseous hibernoma: A metastatic mimicker to consider on the differential Allen Ko, Colin C. Rowell, James B. Vogler, Dmitri E. Samoilov Radiology Case Reports.2020; 15(12): 2677. CrossRef
Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology Yu Jin Kim, Mingi Kim, Hyung Kyu Park, Dan Bi Yu, Kyungsoo Jung, Kyoung Song, Yoon-La Choi Laboratory Investigation.2019; 99(9): 1309. CrossRef
Intraosseous Hibernoma: Five Cases and a Review of the Literature Francisco A. Myslicki, Andrew E. Rosenberg, Ivan Chaitowitz, Ty K. Subhawong Journal of Computer Assisted Tomography.2019; 43(5): 793. CrossRef
Hibernoma Mimicking Atypical Lipomatous Tumor Youssef Al Hmada, Inga-Marie Schaefer, Christopher D.M. Fletcher American Journal of Surgical Pathology.2018; 42(7): 951. CrossRef
Background Clear cell renal cell carcinoma (CCRCC) is presumed to be associated with adipogenic differentiation. Histone modification is known to be important for adipogenesis, and the function of histone demethylase plant homeodomain finger 2 (PHF2) has been noted. In addition, PHF2 may act as a tumor suppressor via epigenetic regulation of p53 and is reported to be reduced in colon cancer and stomach cancer tissues. In this study, we examined PHF2 expression in CCRCC specimens by immunohistochemistry.
Methods We studied 254 CCRCCs and 56 non-neoplastic renal tissues from patients who underwent radical or partial nephrectomy between 2000 and 2003 at the Seoul National University Hospital. Tissue microarray blocks were prepared, and immunohistochemical staining for PHF2 was performed.
Results Among 254 CCRCC cases, 150 cases (59.1%) showed high expression and 104 cases (40.1%) showed low expression. High expression of PHF2 was significantly correlated with a low Fuhrman nuclear grade (p < .001), smaller tumor size (p < .001), low overall stage (p = .003), longer cancer-specific survival (p = .002), and progression-free survival (p < .001) of the patients. However, it was not an independent prognostic factor in multivariate analysis adjusted for Fuhrman nuclear grade and overall stage.
Conclusions Our study showed that low expression of PHF2 is associated with aggressiveness and poor prognosis of CCRCC.
Citations
Citations to this article as recorded by
The role of histone methylation in renal cell cancer: an update Yanguang Hou, Yan Yuan, Yanze Li, Lei Wang, Juncheng Hu, Xiuheng Liu Molecular Biology Reports.2023; 50(3): 2735. CrossRef
Phosphorylation of PHF2 by AMPK releases the repressive H3K9me2 and inhibits cancer metastasis Ying Dong, Hao Hu, Xuan Zhang, Yunkai Zhang, Xin Sun, Hanlin Wang, Weijuan Kan, Min-jia Tan, Hong Shi, Yi Zang, Jia Li Signal Transduction and Targeted Therapy.2023;[Epub] CrossRef
HIF-1α-mediated augmentation of miRNA-18b-5p facilitates proliferation and metastasis in osteosarcoma through attenuation PHF2 Peng Luo, Yan-dong Zhang, Feng He, Chang-jun Tong, Kai Liu, He Liu, Shi-zhuang Zhu, Jian-zhou Luo, Bing Yuan Scientific Reports.2022;[Epub] CrossRef
Integration of meta-analysis and supervised machine learning for pattern recognition in breast cancer using epigenetic data Reza Panahi, Esmaeil Ebrahimie, Ali Niazi, Alireza Afsharifar Informatics in Medicine Unlocked.2021; 24: 100629. CrossRef
PHF2 regulates homology-directed DNA repair by controlling the resection of DNA double strand breaks Ignacio Alonso-de Vega, Maria Cristina Paz-Cabrera, Magdalena B Rother, Wouter W Wiegant, Cintia Checa-Rodríguez, Juan Ramón Hernández-Fernaud, Pablo Huertas, Raimundo Freire, Haico van Attikum, Veronique A J Smits Nucleic Acids Research.2020; 48(9): 4915. CrossRef
Emerging of lysine demethylases (KDMs): From pathophysiological insights to novel therapeutic opportunities Sarder Arifuzzaman, Mst Reshma Khatun, Rabeya Khatun Biomedicine & Pharmacotherapy.2020; 129: 110392. CrossRef
Biology and targeting of the Jumonji-domain histone demethylase family in childhood neoplasia: a preclinical overview Tyler S. McCann, Lays M. Sobral, Chelsea Self, Joseph Hsieh, Marybeth Sechler, Paul Jedlicka Expert Opinion on Therapeutic Targets.2019; 23(4): 267. CrossRef
MiR-221 Promotes Hepatocellular Carcinoma Cells Migration via Targeting PHF2 Yi Fu, Mingyan Liu, Fengxia Li, Li Qian, Ping Zhang, Fengwei Lv, Wenting Cheng, Ruixing Hou BioMed Research International.2019; 2019: 1. CrossRef
PHF2 histone demethylase prevents DNA damage and genome instability by controlling cell cycle progression of neural progenitors Stella Pappa, Natalia Padilla, Simona Iacobucci, Marta Vicioso, Elena Álvarez de la Campa, Claudia Navarro, Elia Marcos, Xavier de la Cruz, Marian A. Martínez-Balbás Proceedings of the National Academy of Sciences.2019; 116(39): 19464. CrossRef
Plant homeodomain finger protein 2 as a novel IKAROS target in acute lymphoblastic leukemia Zheng Ge, Yan Gu, Qi Han, Justin Sloane, Qinyu Ge, Goufeng Gao, Jinlong Ma, Huihui Song, Jiaojiao Hu, Baoan Chen, Sinisa Dovat, Chunhua Song Epigenomics.2018; 10(1): 59. CrossRef
Background Human epidermal growth factor receptor 2 (HER2) is one of the known oncogenes in urothelial carcinoma. However, the association between HER2 and the prognosis of upper urinary tract urothelial carcinoma (UUTUC) has not yet been fully clarified. The aim of this study was to evaluate HER2 expression using the United States Food and Drug Administration (FDA) criteria and American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) criteria and compare their prognostic significance in UUTUC.
Methods HER2 expression was evaluated in 144 cases of UUTUC by immunohistochemistry (IHC) using tissue microarrays. We separately analyzed HER2 expression using the FDA and ASCO/CAP criteria. The IHC results were categorized into low (0, 1+) and high (2+, 3+) groups.
Results Using the FDA criteria, 94 cases were negative, 38 cases were 1+, nine cases were 2+, and three cases were 3+. Using the ASCO/CAP criteria, 94 cases were negative, 34 cases were 1+, 13 cases were 2+, and three cases were 3+. Four cases showing 2+ according to the ASCO/CAP criteria were reclassified as 1+ by the FDA criteria. High HER2 expression by both the FDA criteria and ASCO/CAP criteria was significantly associated with International Society of Urological Pathology high grade (p = .001 and p < .001). The high HER2 expression group classified with the FDA criteria showed significantly shorter cancer-specific survival (p = .004), but the HER2 high and low expression groups classified with the ASCO/CAP criteria did not show significant differences (p = .161) in cancer-specific survival.
Conclusions HER2 high expression groups were significantly associated with shorter cancer-specific survival, and our study revealed that the FDA criteria are more suitable for determining HER2 expression in UUTUC.
Citations
Citations to this article as recorded by
A systematic review and meta-analysis for human epidermal growth factor receptor 2 on upper tract urothelial carcinoma patients Jianjun Ye, Xinyang Liao, Yu Qiu, Qiang Wei, Yige Bao Tumori Journal.2024; 110(1): 25. CrossRef
ERBB2 Amplification as a Predictive and Prognostic Biomarker in Upper Tract Urothelial Carcinoma Annette Zimpfer, Said Kdimati, Melanie Mosig, Henrik Rudolf, Heike Zettl, Andreas Erbersdobler, Oliver W. Hakenberg, Matthias Maruschke, Björn Schneider Cancers.2023; 15(9): 2414. CrossRef
Near-Infrared Photoimmunotherapy (NIR-PIT) in Urologic Cancers Hiroshi Fukushima, Baris Turkbey, Peter A. Pinto, Aki Furusawa, Peter L. Choyke, Hisataka Kobayashi Cancers.2022; 14(12): 2996. CrossRef
Assessment of HER2 Protein Overexpression and Gene Amplification in Renal Collecting Duct Carcinoma: Therapeutic Implication Manuela Costantini, Carla Azzurra Amoreo, Liborio Torregrossa, Greta Alì, Enrico Munari, Carmen Jeronimo, Rui Henrique, Sara Petronilho, Umberto Capitanio, Roberta Lucianò, Nazareno Suardi, Maria Teresa Landi, Umberto Anceschi, Aldo Brassetti, Vito Michel Cancers.2020; 12(11): 3345. CrossRef